Bao-min Du

  • Citations Per Year
Learn More
OBJECTIVES To evaluate whether lipid-lowering therapy with xuezhikang reduces the risk of coronary events and total mortality in patients with coronary heart disease (CHD) aged 65 and older. DESIGN Subgroup analysis of the China Coronary Secondary Prevention Study, a randomized, double-blind, placebo-controlled, clinical trial. SETTING Sixty-six(More)
OBJECTIVE To assess whether Xuezhikang was effective in the secondary prevention of coronary heart disease (CHD) for patients with different length of myocardial infarction (MI) history. METHODS 2135 patients with MI history of 28 days to 3 months and 2735 patients with MI history of 3 months to 60 months were recruited separately to receive treatment(More)
OBJECTIVE To discuss the diagnosis and properly treatment to the adult adenoidal hypertrophy. METHOD To do nasal endoscopic and pathologic exam to all the 20 symptomatic patients before conservative or operative treatment. RESULT The results of exam under endoscope were that 8 patients were hypertrophy I, 8 hypertrophy II, 4 hypertrophy III. Pathologic(More)
UNLABELLED The right ventricular volumes and ejection fraction (RVEF) obtained from two-dimensional echocardiography and from right ventricular angiography were compared in 20 patients with congenital heart disease. Single plane area-length method of apical four-chamber view was used to estimate echocardiographic right ventricular volumes and single plane(More)
OBJECTIVE To elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease (CHD) patients with diabetes. METHODS We designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule(More)
Lipid-lowering therapy has been proven to reduce macrovascular complications of type 2 diabetes. Xuezhikang is an extract of cholestin and has a markedly modulating effect on lipids, but the effect of xuezhikang on reducing coronary events in diabetic patients with coronary heart disease (CHD) is less clear. A total of 591 diabetic patients with CHD were(More)
OBJECTIVE To evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in coronary heart disease (CHD) patients with or without hypertension. METHODS In this random, double-blinded, placebo controlled clinical trial, 2704 patients with hypertension and 2166 patients without hypertension were enrolled(More)
  • 1